New HIV study offers patients a choice: daily pill or bimonthly shot

NCT ID NCT05917509

Completed Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two ways to control HIV in 171 adults who had never been treated before. Everyone started with a daily pill (dolutegravir/lamivudine). Once the virus was undetectable, participants could choose to switch to a shot (cabotegravir plus rilpivirine) given every two months or stay on the pill. The goal was to see how well each option kept the virus suppressed and how patients felt about their treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Birmingham, Alabama, 35205, United States
GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

Fort Lauderdale, Florida, 33308, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Orlando, Florida, 32804, United States
GSK Investigational Site

Pensacola, Florida, 32504, United States
GSK Investigational Site

Berkley, Michigan, 48072, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

Omaha, Nebraska, 68198, United States
GSK Investigational Site

Henderson, Nevada, 89106, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Huntersville, North Carolina, 28078, United States
GSK Investigational Site

Beaumont, Texas, 77701, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Fort Worth, Texas, 76104, United States
GSK Investigational Site

Buenos Aires, C1202, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, 1405, Argentina
GSK Investigational Site

Mar del Plata, B7600DHK, Argentina
GSK Investigational Site

Rosario, S2013, Argentina
GSK Investigational Site

Hamilton, Ontario, L8S 1A4, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

La Cisterna, 7970000, Chile
GSK Investigational Site

Providencia, 7500000, Chile
GSK Investigational Site

Santiago, 9500000, Chile
GSK Investigational Site

Temuco, 4780000, Chile
GSK Investigational Site

Créteil, 94000, France
GSK Investigational Site

Orléans, 45067, France
GSK Investigational Site

Paris, 75004, France
GSK Investigational Site

Paris, 75015, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Düsseldorf, 40225, Germany
GSK Investigational Site

Frankfurt am Main, 60329, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

München, 80337, Germany
GSK Investigational Site

Foggia, 71100, Italy
GSK Investigational Site

Milan, 20127, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Roma, 00149, Italy
GSK Investigational Site

Ponce, 00717-1563, Puerto Rico
GSK Investigational Site

Almería, 04009, Spain
GSK Investigational Site

Granada, 35016, Spain
GSK Investigational Site

La Laguna-Tenerife, 35010, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28031, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Murcia, 30008, Spain
GSK Investigational Site

Seville, 41071, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.